A phase 2 clinical trial of axitinib and avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (ACC).

被引：0
|
作者：
Ferrarotto, Renata
Bell, Diana
Feng, Lei
Li, Kaiyi
Mott, Frank
Blumenschein, George R.
De Sousa, Luana Guimaraes
Altan, Mehmet
Marques-Piubelli, Mario L.
Dal Lago, Eduardo Andreazza
Kaya, Diana
Godoy, Myrna
Kupferman, Michael Elliot
Glisson, Bonnie S.
El-Naggar, Adel K.
Elamin, Yasir Y.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX USA
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Biostatist, Houston, TX USA
[4] MD Anderson Canc Ctr, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Head & Neck Med Oncol, Houston, TX USA
[7] Univ Sao Paulo, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6019
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II study of lenvatinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
    Tchekmedyian, Vatche
    Sherman, Eric Jeffrey
    Dunn, Lara
    Tran, Crystal
    Katabi, Nora
    Ni, Ai
    Haque, Sofia
    Pfister, David G.
    Ho, Alan Loh
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma
    Keam, Bhumsuk
    Kim, Sung-Bae
    Shin, Seong Hoon
    Cho, Byoung Chul
    Lee, Keun-Wook
    Kim, Min Kyoung
    Yun, Hwan-Jung
    Lee, Se-Hoon
    Yoon, Dok Hyun
    Bang, Yung-Jue
    CANCER, 2015, 121 (15) : 2612 - 2617
  • [23] A phase II study of suberoylanilide hydroxamic acid (SAHA) in subjects with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC)
    Goncalves, Priscila Hermont
    Kummar, Shivaani
    Siu, Lillian L.
    Hansen, Aaron Richard
    Savvides, Panayiotis
    Sukari, Ammar
    Chao, Joseph
    Heilbrun, Lance K.
    Pilat, Mary Jo
    Smith, Daryn W.
    Casetta, Lindsay
    Boerner, Scott Anthony
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] LOCAL CONTROL FOLLOWING COMBINATION HYPOFRACTIONATED RADIOTHERAPY AND PEMBROLIZUMAB IN A PHASE II TRIAL OF RECURRENT OR METASTATIC ADENOID CYSTIC CARCINOMA PATIENTS
    Bang, Andrew
    Mahmood, Umair
    Chen, Yu-Hui
    Mak, Raymond H.
    Lorch, Jochen H.
    Hanna, Glenn J.
    Sridharan, Vishwajith
    Busse, Paul M.
    Willers, Henning
    Mamon, Harvey J.
    Yoo, Hyung-Jin
    Pai, Sara I.
    Wirth, Lori J.
    Haddad, Robert I.
    Chau, Nicole G.
    Schoenfeld, Jonathan D.
    RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S26 - S27
  • [25] Local Control following Combination Hypofractionated Radiotherapy and Pembrolizumab in A Phase II Trial of Recurrent or Metastatic Adenoid Cystic Carcinoma Patients
    Bang, A.
    Mahmood, U.
    Chen, Y. H.
    Mak, R. H.
    Lorch, J.
    Hanna, G. J.
    Sridharan, V.
    Busse, P. M.
    Willers, H.
    Mamon, H. J.
    Yoo, H. J.
    Pai, S. I.
    Wirth, L.
    Haddad, R. I.
    Chau, N.
    Schoenfeld, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E363 - E363
  • [26] Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma
    Ho, Allen S.
    Ochoa, Angelica
    Jayakumaran, Gowtham
    Zehir, Ahmet
    Mayor, Cristina Valero
    Tepe, Justin
    Makarov, Vladimir
    Dalin, Martin G.
    He, Jie
    Bailey, Mark
    Montesion, Meagan
    Ross, Jeffrey S.
    Miller, Vincent A.
    Chan, Lindsay
    Ganly, Ian
    Dogan, Snjezana
    Katabi, Nora
    Tsipouras, Petros
    Ha, Patrick
    Agrawa, Nishant
    Solit, David B.
    Futreal, P. Andrew
    El Naggar, Adel K.
    Reis-Filho, Jorge S.
    Weigelt, Britta
    Ho, Alan L.
    Schultz, Nikolaus
    Chan, Timothy A.
    Morris, Luc G. T.
    JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (10): : 4276 - 4289
  • [27] Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma
    Xu, Melody J.
    Wu, Tara J.
    van Zante, Annemieke
    El-Sayed, Ivan H.
    Algazi, Alain P.
    Ryan, William R.
    Ha, Patrick K.
    Yom, Sue S.
    JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2018, 47 : 28
  • [28] Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma
    Melody J. Xu
    Tara J. Wu
    Annemieke van Zante
    Ivan H. El-Sayed
    Alain P. Algazi
    William R. Ryan
    Patrick K. Ha
    Sue S. Yom
    Journal of Otolaryngology - Head & Neck Surgery, 47
  • [29] AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
    Ferrarotto, R.
    Bobbili, P.
    Bowles, D. W.
    Even, C.
    Gordon, G.
    Gutierrez, A.
    Metcalf, R.
    Muzaffar, J.
    Nguyen, C.
    Oliva, M.
    Perez, C. A.
    Rodriguez, C.
    Sendhil, S. R.
    Winquist, E.
    Wirth, L. J.
    Xia, B.
    Yovell, J.
    Ho, A. L.
    ANNALS OF ONCOLOGY, 2023, 34 : S575 - S576
  • [30] Axitinib in recurrent or metastatic nasopharyngeal carcinoma (NPC): final result of a phase 2 clinical trial with pharmacokinetic (PK) correlation
    Hui, E. P.
    Ma, B. B.
    Mo, F.
    Kam, M. K.
    Chan, S. L.
    Loong, H. H.
    Ho, R.
    Leung, S. F.
    King, A. D.
    Wang, K.
    Ahuja, A.
    Chan, C. M.
    Hui, C. W.
    Wong, C. H.
    Chan, A. T. C.
    ANNALS OF ONCOLOGY, 2016, 27
12345